首页> 外文期刊>AIDS Research and Human Retroviruses >Changes in the renal function after tenofovir-containing antiretroviral therapy initiation in a Senegalese cohort (ANRS 1215).
【24h】

Changes in the renal function after tenofovir-containing antiretroviral therapy initiation in a Senegalese cohort (ANRS 1215).

机译:塞内加尔队列中含替诺福韦的抗逆转录病毒治疗开始后肾功能的变化(ANRS 1215)。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

To describe and compare the changes in renal function between HIV-1 infected adult patients receiving antiretroviral therapy (ART) with and without tenofovir (TDF). The population consisted of 40 patients starting a TDF-containing regimen and 388 patients starting regimen not containing TDF, and followed during 42 months. The estimated glomerular filtration rate (eGFR) was calculated using the Cockroft-Gault and MDRD equations and modeled separately for the first 12 months and the subsequent period. Between baseline and 12 months, the eGFR decreased significantly in patients receiving TDF (-10.40 ml/min), whereas it increased in the other +4.33 ml/min). A significant variability in the eGFR trajectories of patients receiving TDF was observed; 12 (30%) of them experienced a persistent decrease, 5 (12%) had an initial transient increase, and 23 (58%) a steady slow increase in eGFR. The characteristics at baseline of the patients with persistent decrease were not different from the other patients but their immune reconstitution was impaired. After 12 months, patients receiving TDF experienced a higher rate of transition from mild renal impairment (60-90 ml/min/1.73 m(2)) to moderate renal impairment (30-60 ml/min/1.73 m(2)) when compared with patients not receiving TDF. A significant though moderate decline in the renal function was observed in one-third of the patients receiving TDF compared to patients not receiving TDF. Moreover, this impairment was persistent after the first year of treatment.
机译:描述和比较接受抗逆转录病毒治疗(ART)和有或没有替诺福韦(TDF)的HIV-1感染成人患者之间肾功能的变化。该人群由40位开始使用TDF方案的患者和388位开始不包含TDF方案的患者组成,随访时间为42个月。估计的肾小球滤过率(eGFR)使用Cockroft-Gault和MDRD方程计算,并分别在前12个月和随后的阶段建模。在基线至12个月之间,接受TDF的患者的eGFR显着下降(-10.40 ml / min),而其他+4.33 ml / min则升高。观察到接受TDF的患者的eGFR轨迹存在显着差异;其中有12(30%)的患者持续下降,其中5(12%)的患者初期eGFR持续升高,而23(58%)的患者eGFR持续缓慢增长。持续减少的患者的基线特征与其他患者没有什么不同,但是他们的免疫重建受到损害。 12个月后,接受TDF的患者从轻度肾功能不全(60-90 ml / min / 1.73 m(2))转变为中度肾功能不全(30-60 ml / min / 1.73 m(2))的比率更高。与未接受TDF的患者相比。与未接受TDF的患者相比,接受TDF的患者中有三分之一的患者肾功能显着下降。而且,这种损伤在治疗的第一年后仍然持续存在。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号